Stockreport

PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights

PepGen Inc.  (PEPG) 
PDF – FREEDOM2-DM1 5 mg/kg cohort data expected in Q1 2026 –– Patient dosing in the FREEDOM2 10 mg/kg cohort is proceeding in Canada and the UK, with data expected in 2H 202 [Read more]